[Featured Stock] Hanmi Pharm Gains Over 3% on US FDA Approval of New Drug 'Rollontis'

[Asia Economy Reporter Lee Myunghwan] Hanmi Pharm is showing strong performance in early trading on the 13th. This appears to be due to the approval of the company's new drug for neutropenia treatment, 'Rolontis,' by the U.S. Food and Drug Administration (FDA).

As of 9:20 a.m. today, Hanmi Pharm is trading at 312,000 KRW, up 3.31% (10,000 KRW) from the previous trading day.

On the 9th (local time), Hanmi Pharm announced that its U.S. partner, Spectrum Pharmaceuticals, which licensed Rolontis, received a notification of approval from the FDA for the marketing authorization of 'Rolvedon' (the U.S. product name for Rolontis).

Rolontis is the first new drug developed by Hanmi Pharm to receive FDA approval. It is the first anticancer new drug in South Korea and the sixth FDA approval case among new drugs developed by domestic pharmaceutical companies. Rolontis is also the first bio-drug using Hanmi Pharm's proprietary platform technology, 'Lapscovery,' to receive global market approval. Lapscovery is a technology that extends the drug's duration in the body, overcoming the short half-life, which is considered a drawback of biopharmaceuticals.

The securities industry also views this FDA approval as a potential new growth driver. Kwon Haesoon, a researcher at Eugene Investment & Securities, stated, "We believe that the U.S. sales of Rolontis and Poziotinib can serve as new profit growth drivers that offset the potential slowdown in Hanmi Pharm's domestic growth." He analyzed, "Assuming a 2023 launch, the combined sales of the two products in the fifth year after launch, 2027, are estimated to be about 450 billion KRW, and the profit reflected to Hanmi Pharm based on operating profit is estimated to be about 60 billion KRW, which would be approximately 38% of this year's operating profit."

This content was produced with the assistance of AI translation services.